Efficiency of viferon therapy in infants with acute respiratory virus infection

The impact of VIFERON therapy on clinical, immunological, and virological characteristics was evaluated in 40 children aged 1 month to 3,5 years with acute respiratory virus infection. Study group patients (n=20) received a treatment cycle of VIFERON® in a daily dose of 1 000 000 IU. Comparison grou...

Full description

Bibliographic Details
Main Authors: N. V. Okolysheva, L. B. Kisteneva, E. N. Vyzhlova, V. V. Malinovskaya, S. G. Cheshik, V. V. Parfenov, E. A. Ruzhitskaya, A. V. Semenov, A. P. Fisenko
Format: Article
Language:Russian
Published: Ltd. “The National Academy of Pediatric Science and Innovation” 2016-03-01
Series:Rossijskij Vestnik Perinatologii i Pediatrii
Subjects:
Online Access:https://www.ped-perinatology.ru/jour/article/view/101
Description
Summary:The impact of VIFERON therapy on clinical, immunological, and virological characteristics was evaluated in 40 children aged 1 month to 3,5 years with acute respiratory virus infection. Study group patients (n=20) received a treatment cycle of VIFERON® in a daily dose of 1 000 000 IU. Comparison group patients (n=20) had symptomatic treatment only. The investigators revealed IgM and IgG antibodies to cytomegalovirus, Epstein—Barr virus, and human herpesvirus 6 and determined herpesvirus DNA in blood, saliva, and urine and respiratory virus DNA/RNA in nasopharyngeal swabs. Flow cytofluorometry was used to study the quantitative composition of lymphocytes with phenotypes CD3+, CD3+4+, CD3+8+, CD3-16+56+, and CD3+CD16+CD56+. The efficiency of VIFERON® therapy was evaluated comparing the results of examinations of the children before and 7 days after treatment. In the study group, the VIFERON® therapy-induced elimination rate for rhinovirus, metapneumovirus, and influenza virus A accounted for 100% and that for respiratory syncytial virus and adenovirus was 87,5 and 66,7%, respectively. In the comparison group, the elimination rate for rhinovirus accounted for 66,7% and that for respiratory syncytial virus and adenoviruses was 0%. The effiacy of VIFERON® against herpesviruses was lower than that against respiratory viruses although Epstein–Barr virus and human herpesvirus 6 eliminations were significantly more frequently noted in the study group patients. In this group, there was accelerated resolution of inflammation, a more pronounced immunotropic effect, including an antiviral effect, than in the comparison group.
ISSN:1027-4065
2500-2228